Kumar Anil, Girdhar Anita, Girdhar B K
Epidemiology & Clinical Divisions, National JALMA Institute for Leprosy & Other Mycobacterial Diseases (ICMR), Agra, India.
Indian J Med Res. 2013 Oct;138(4):536-40.
BACKGROUND & OBJECTIVES: The reported low relapse rates after 24 months multidrug therapy (MDT) for multibacillary leprosy (MB) led to the recommendation of reducing duration of therapy to 12 months. However, only a few reports exist on long term follow up data after 12 months fixed duration therapy (FDT). The present study was done to assess the incidence of relapse in MB leprosy patients after 12 months treatment.
The leprosy patients detected in field surveys during 2001-2006 in Agra district, Uttar Pradesh, India, were put on WHO-MDT and followed up for treatment completion, relapse, reactions and development of disability. The assessment was done clinically by following up the patients until January 2011. Data collected were analyzed for risk and survival analysis.
The incidence of relapse was found to be 1.97/100 person years of follow up. The incidence of relapse by age (34 yr vs >34 yr), sex (male vs female), delay in detection (<36 months vs >36 months) and smear status (smear +ve vs -ve) was not found to be significantly different but patients with no nerve involvement were observed to have significantly higher relapses than those with three or more nerve involvement (P<0.05). Similarly, borderline-borderline and BB with reaction (BB/BBR) patients were observed to have significantly high relapses than among those with borderline tuberculoid or BT with reaction (BT/BTR) or borderline lipromatous/lepromatous/neuritic (BL/LL/N) type of leprosy (P<0.01).
INTERPRETATION & CONCLUSION: From the observations in the study, it can be suggested that relapses occur in 12 months FDT and almost as much as reported in 24 months FDT for MB leprosy. Although, early relapses may be due to insufficient treatment, late relapses may be due to persistent dormant mycobacteria. However, a study relating to immunological response of treatment and change in immunological profile relating to the occurrence of relapses and its clinical correlates may suggest better information on causes of relapses.
有报告称,多菌型麻风(MB)患者接受24个月的多药联合治疗(MDT)后复发率较低,因此建议将治疗疗程缩短至12个月。然而,关于12个月固定疗程治疗(FDT)后的长期随访数据的报告较少。本研究旨在评估MB麻风患者接受12个月治疗后的复发率。
对2001年至2006年期间在印度北方邦阿格拉地区的现场调查中发现的麻风患者采用世界卫生组织的多药联合治疗方案,并对其治疗完成情况、复发情况、反应及残疾发展进行随访。通过对患者进行随访直至2011年1月来进行临床评估。对收集的数据进行风险分析和生存分析。
发现复发率为每100人年随访1.97例。未发现复发率在年龄(34岁与大于34岁)、性别(男性与女性)、发现延迟(<36个月与>36个月)及涂片状态(涂片阳性与阴性)方面存在显著差异,但未累及神经的患者复发率显著高于累及三条或更多神经的患者(P<0.05)。同样,观察发现,中间界线类-中间界线类和有反应的界线类偏瘤型(BB/BBR)患者的复发率显著高于界线类偏结核样型或有反应的结核样型(BT/BTR)或界线类偏瘤型/瘤型/神经炎型(BL/LL/N)麻风患者(P<0.01)。
从本研究的观察结果可以看出,MB麻风患者在12个月固定疗程治疗中会出现复发,且复发率几乎与24个月固定疗程治疗的报告复发率相同。虽然早期复发可能是由于治疗不足,但晚期复发可能是由于持续存在的潜伏分枝杆菌。然而,一项关于治疗的免疫反应以及与复发发生相关的免疫谱变化及其临床关联的研究,可能会提供关于复发原因的更好信息。